Prelude Therapeutics Inc
PRLD
Company Profile
Business description
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
Contact
175 Innovation Boulevard
WilmingtonDE19805
USAT: +1 302 467-1280
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
128
Stocks News & Analysis
stocks
5 undervalued US shares that crushed earnings
These stocks are still cheap despite impressive earnings.
stocks
Undervalued ASX listed biotech refocuses
Fair value uneffected by suspended early-stage clinical trials.
stocks
We lift our fair value in wide moat ASX share
Signs of improvement in continued improvement in core business.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,629.20 | 74.80 | 0.87% |
| CAC 40 | 7,194.51 | 83.72 | -1.15% |
| DAX 40 | 18,986.21 | 202.98 | -1.06% |
| Dow JONES (US) | 43,389.60 | 55.39 | -0.13% |
| FTSE 100 | 8,079.22 | 30.10 | -0.37% |
| HKSE | 19,663.67 | 87.06 | 0.44% |
| NASDAQ | 18,791.81 | 111.69 | 0.60% |
| Nikkei 225 | 38,414.43 | 193.58 | 0.51% |
| NZX 50 Index | 12,816.32 | 51.67 | 0.40% |
| S&P 500 | 5,893.62 | 23.00 | 0.39% |
| S&P/ASX 200 | 8,374.00 | 73.80 | 0.89% |
| SSE Composite Index | 3,346.01 | 22.16 | 0.67% |